Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Insights and Forecast to 2028

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market by Application
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Adult
1.3.3 Pediatric
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
2.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region (2023-2028)
2.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
2.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022)
2.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers
3.1.1 Global Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2021
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type
4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022)
4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application
5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022)
5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
6.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
6.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
6.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
6.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
6.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
6.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
6.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
6.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
7.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
7.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
7.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
8.1.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
8.2.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
8.3.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
9.1.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
9.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
9.2.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
9.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
9.3.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
10.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
10.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.3.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Corporation Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Protein Sciences Corporation
11.3.1 Protein Sciences Corporation Corporation Information
11.3.2 Protein Sciences Corporation Overview
11.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Protein Sciences Corporation Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis AG Recent Developments
11.5 Seqirus
11.5.1 Seqirus Corporation Information
11.5.2 Seqirus Overview
11.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Seqirus Recent Developments
11.6 Merck Sharp & Dohme Corp
11.6.1 Merck Sharp & Dohme Corp Corporation Information
11.6.2 Merck Sharp & Dohme Corp Overview
11.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Merck Sharp & Dohme Corp Recent Developments
11.7 Astellas Pharma US
11.7.1 Astellas Pharma US Corporation Information
11.7.2 Astellas Pharma US Overview
11.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Astellas Pharma US Recent Developments
11.8 Pfizer Inc
11.8.1 Pfizer Inc Corporation Information
11.8.2 Pfizer Inc Overview
11.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Inc Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Corporation Information
11.9.2 Johnson & Johnson Overview
11.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Johnson & Johnson Recent Developments
11.10 Lanzhou Institute of Biological Products Co., Ltd
11.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
11.10.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Corporation Information
11.11.2 AstraZeneca Overview
11.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AstraZeneca Recent Developments
11.12 Emergent BioSolutions Inc
11.12.1 Emergent BioSolutions Inc Corporation Information
11.12.2 Emergent BioSolutions Inc Overview
11.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Emergent BioSolutions Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Chain Analysis
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
12.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
12.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
12.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
13.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
14 Key Findings in The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Immune DTaP Vaccine
Table 3. Major Manufacturers of Therapy DTaP Vaccine
Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2021)
Table 21. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2017-2022)
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2023-2028)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2023-2028)
Table 33. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2017-2022)
Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2023-2028)
Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2023-2028)
Table 43. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
Table 45. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 47. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 50. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 51. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 54. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 55. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 58. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 59. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 62. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 63. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 66. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 67. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 70. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 71. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 74. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 75. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 78. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 79. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 82. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 83. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 86. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 87. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 90. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 91. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 94. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 95. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 98. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 99. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 102. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 103. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sanofi Pasteur Corporation Information
Table 106. Sanofi Pasteur Description and Major Businesses
Table 107. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 108. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sanofi Pasteur Recent Developments
Table 110. GlaxoSmithKline Corporation Information
Table 111. GlaxoSmithKline Description and Major Businesses
Table 112. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 113. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GlaxoSmithKline Recent Developments
Table 115. Protein Sciences Corporation Corporation Information
Table 116. Protein Sciences Corporation Description and Major Businesses
Table 117. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 118. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Protein Sciences Corporation Recent Developments
Table 120. Novartis AG Corporation Information
Table 121. Novartis AG Description and Major Businesses
Table 122. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 123. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Novartis AG Recent Developments
Table 125. Seqirus Corporation Information
Table 126. Seqirus Description and Major Businesses
Table 127. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 128. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Seqirus Recent Developments
Table 130. Merck Sharp & Dohme Corp Corporation Information

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs